New category of probable invasive pulmonary aspergillosis in haematological patients

Clinical Microbiology and Infection

Volumn 18, Issue 10, 2012, Pages 990-996

  Girmenia, C ^a   Guerrisi, P ^a   Frustaci, A M ^a   Fama, A ^a   Finolezzi, E ^a   Perrone, S ^a   Gentile, G ^a   Collerone, F ^a   Brocchieri, S ^a   Guerrisi, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Definition; Haematological malignancies; Invasive pulmonary aspergillosis; Radiological findings

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION RISK; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; RADIODIAGNOSIS; RECOMMENDED DRUG DOSE; SURVIVAL; TREATMENT RESPONSE;

ASPERGILLUS;

EID: 84866165930     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03685.x     Document Type: Article

References (15)

1. Segal BH. Aspergillosis. N Engl J Med 2009; 360: 1870-1884.
2. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
3. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
4. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
5. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
6. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
7. Hachem R, Sumoza D, Hanna H, Girgawy E, Munsell M, Raad I. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 2006; 106: 1581-1586.
8. Sinko J, Csomor J, Nikolova R et al. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis 2008; 10: 106-109.
9. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003; 82: 80-82.
10. Nucci M, Nouér SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010; 51: 1273-1280.
11. Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-674.
12. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapyand study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensuscriteria. Clin Infect Dis 2008; 47: 674-683.
13. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-1281.
14. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56-e93.
15. Maertens J, Marchetti O, Herbrecht R et al., European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant. Bone Marrow Transplant 2011; 46: 708-718.